Send us a Message

*
*
*
*

Guildford, UK

ID Business Solutions Ltd.

2 Occam Court
Surrey Research Park
Guildford, Surrey
GU2 7QB
United Kingdom

Tel: +44 1483 595 000
Fax: +44 1483 595 001

London, UK

ID Business Solutions Ltd.

4th Floor, Pembroke Building
Kensington Village
Avonmore Road
London, W14 8DG
United Kingdom

Tel: +44 207 565 8620
Fax: +44 207 565 8700

Paris, France

ID Business Solutions Ltd.

18 Rue Pasquier,
Paris, 75008
France

Tel: +33 01 78 41 44 46

Alameda, California

ID Business Solutions Inc.

1301 Marina Village Parkway
Suite 320,
Alameda, CA 94501

Tel: +1 510 814 4900
Fax: +1 510 814 4910

Bridgewater, New Jersey

ID Business Solutions Inc.

750 US Highway 202,
Suite 200,
Bridgewater, NJ 08807

Tel: +1 908 429 2900
Fax: +1 908 429 2901

Burlington, Massachusetts

ID Business Solutions Inc.

25 Burlington Mall Road
1st Floor, Suite #107
Burlington, MA 01803

Tel: +1 781 272 3355
Fax: +1 781 272 3377

Chicago, Illinois

ID Business Solutions Inc.

8770 W. Bryn Mawr,
Suite 1300,
Chicago, IL 60631

Tel: +1 773 867 2958

Tokyo, Japan

ID Business Solutions (Japan)

Shibuya Mark City W22F
1-12-1 Dogenzaka Shibuya-ku Tokyo
150-0043 Japan

Tel: +81 3 4360 5344
info-japan@idbs.com

Bangalore, India

Tel: +91-990-0064-922
+91-080-2587-0336

Shanghai, China

ID Business Solutions

Room 207, Block A, Innovation Building
NO.333 Cailun Road, Zhangjiang High Tech. Park
Shanghai 201203
China

Tel: +86-21-6468-5535/6469-1770
Fax: +86-21-6468-5366

Melbourne, Australia

Conor Higgins
PO box 9079
Brighton
Melbourne
Vic 3186

Conor Higgins - chiggins@idbs.com
Tel: +61 410 708 052

Close

Follow IDBSsoftware on Twitter

IDBS Press Release

IDBS to Power Personalized Cancer Care at King’s Health Partners with Enterprise Translational Medicine Platform

Hosted Solution will Improve Patient Outcomes, Research and Collaboration by Integrating Clinical and Molecular Data from Three Major National Health Service Trusts and Leading University

Guildford, UK, and Burlington, Mass., March 9, 2011 - IDBS, a global provider of innovative data management, analytics and modeling solutions, today announced that it will provide a unique, enterprise translational medicine platform for the Integrated Cancer Centre at King’s Health Partners. The Oncology Research Information System, (ORIS), designed at the Integrated Cancer Centre and developed and delivered by IDBS, will enable King’s Health Partners to develop targeted, personalized, cancer therapies according to the specific genetic and other characteristics of individual patients. This will improve the likelihood and number of successful treatment outcomes.

ORIS is the first of its kind: a single cross-organizational research platform that will bring together patient data for all King’s Health Partner’s cancer cases, accounting for a quarter of hospital beds in London. This comprehensive approach to cancer research has never before been able to be handled in one IT platform. ORIS will provide a unique translational medicine hub, handling the complex analytical demands of translational research and improving collaboration between the partners - King’s College London University, King’s College Hospital, Guy’s and St Thomas’ and South London and the Maudsley NHS Foundation Trusts.

IDBS, through the ORIS platform and associated organizational changes, will provide King’s Health Partners with:

  • improved cancer treatment through secure knowledge sharing of patient outcome information;
  • one secure searchable hub for clinical, diagnostic, pathological, sample, research and genomics centric information integrated from multiple sources;
  • highly secure information governance and pseudonymization procedures to protect patient confidentiality;
  • comprehensive scientific and statistical analytics to support requirements across research, teaching and clinical needs;
  • reduced complexity with high security through scalable, flexible hosting and rigorous access control;
  • powerful visualization of translational research data and an evaluation of data quality;
  • an enhanced competitive position for attracting pharmaceutical and other research partners.

“Despite all the progress medical science has made, many cancer patients are still treated with protocols identified through a process of trial and error. Our aim is to change this through a targeted approach to cancer therapy, which will improve outcomes and patient quality of life,” said Professor Peter Parker, PhD, FRS, Head of the Division of Cancer Studies and R&D Lead for the Integrated Cancer Centre at King’s Health Partners. “Critical to this effort is a new collaboration between the different research and healthcare organizations involved and, above all, access to relevant data and analytics to enable our multi-disciplinary research teams to deliver outcome-based therapies.”   

“During our extensive competitive tender process, IDBS clearly demonstrated a unique understanding of the complexities of translational medicine, core software provision and solution integration that we required for this program,” continued Professor Parker. 

“IDBS understands that the improvement of patient outcomes will come from the successful delivery of targeted treatments, which requires a fundamental change in the approach healthcare organizations take to using increasingly complex research information and sharing of the clinical knowledge they generate,” said Neil Kipling, founder and CEO of IDBS. “Our broad understanding of the healthcare and pharmaceutical research sectors enables us to deliver the enabling technologies required to make the promise of personalized medicine a reality. The ORIS project further validates our strategy to design and build enterprise data management and analytics systems targeted at improving healthcare provision in the UK and worldwide.”

This is the first step in a five-year strategic relationship that could eventually expand to cover all disease areas including all oncology disorders and cardiovascular disease.

About King’s Health Partners

King’s Health Partners Academic Health Sciences Centre (AHSC) is a pioneering collaboration between King’s College London, and Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts

King’s Health Partners is one of only five AHSCs in the UK and brings together an unrivalled range and depth of clinical and research expertise, spanning both physical and mental health. Our combined strengths will drive improvements in care for patients, allowing them to benefit from breakthroughs in medical science and receive leading edge treatment at the earliest possible opportunity.

For more information, visit www.kingshealthpartners.org

About IDBS

IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.

IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, high-tech materials and consumer products, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and products.

Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a 2010 Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan 'Enabling Technology' Award in R&D data management for 2010 and Queen's Award for International Trade 2011. For regular updates follow us on Twitter @IDBSsoftware

For media enquiries, please contact:

Danielle Guinebertiere, IDBS Communications Director
Tel: +1 908 429 2933
Email: dguinebertiere@idbs.com